Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Earnings

Review historical estimates and see whether a company has beaten or missed expectations.

Last Close
Jun 14 04:00PM ET
29.00
Dollar change
-0.80
Percentage change
-2.68
%
Index- P/E- EPS (ttm)-2.37 Insider Own- Shs Outstand27.19M Perf Week-6.45%
Market Cap784.16M Forward P/E- EPS next Y-7.49 Insider Trans- Shs Float- Perf Month7.67%
Income-65.37M PEG- EPS next Q- Inst Own0.09% Short Float- Perf Quarter16.47%
Sales3.33M P/S235.48 EPS this Y-188.54% Inst Trans14.45% Short Ratio1.97 Perf Half Y48.53%
Book/sh17.07 P/B1.70 EPS next Y-8.17% ROA-9.36% Short Interest0.00M Perf Year13.68%
Cash/sh12.16 P/C2.39 EPS next 5Y- ROE-12.99% 52W Range17.08 - 34.00 Perf YTD2.91%
Dividend Est.- P/FCF- EPS past 5Y-8.32% ROI-13.55% 52W High-14.71% Beta1.23
Dividend TTM- Quick Ratio6.76 Sales past 5Y-14.77% Gross Margin-47.75% 52W Low69.79% ATR (14)1.25
Dividend Ex-Date- Current Ratio6.76 EPS Y/Y TTM-30.96% Oper. Margin-4375.56% RSI (14)50.71 Volatility0.76% 1.37%
Employees- Debt/Eq0.05 Sales Y/Y TTM-79.25% Profit Margin-1964.02% Recom1.00 Target Price79.61
Option/ShortNo / Yes LT Debt/Eq0.04 EPS Q/Q-78.59% Payout- Rel Volume0.05 Prev Close29.80
Sales Surprise-97.00% EPS Surprise53.85% Sales Q/Q-98.02% EarningsApr 25 BMO Avg Volume2.44K Price29.00
SMA200.41% SMA504.13% SMA20014.77% Trades Volume130 Change-2.68%
Jun-13-24 01:15PM
Jun-06-24 12:38PM
May-29-24 08:09AM
May-23-24 07:00AM
May-21-24 07:05AM
06:35AM Loading…
May-20-24 06:35AM
02:00AM
May-09-24 07:05AM
May-07-24 07:05AM
Apr-30-24 08:37AM
Apr-25-24 05:22AM
Apr-18-24 02:00AM
Apr-16-24 07:00AM
Apr-11-24 07:00AM
Apr-09-24 08:19AM
02:00AM Loading…
02:00AM
Apr-02-24 08:50AM
Mar-19-24 03:00AM
Mar-18-24 09:52AM
Mar-13-24 07:00AM
Feb-27-24 07:00AM
02:00AM
Feb-15-24 09:35AM
Jan-03-24 07:00AM
Dec-22-23 09:13AM
Dec-20-23 02:00AM
Dec-07-23 06:00AM
Nov-29-23 10:17AM
Nov-17-23 02:00AM
Nov-14-23 02:00AM
02:00AM Loading…
Oct-17-23 02:00AM
Oct-11-23 07:00AM
Oct-04-23 07:05AM
Sep-28-23 07:38AM
Sep-27-23 02:05AM
Aug-30-23 01:04AM
Aug-22-23 02:00AM
Aug-01-23 07:00AM
Jun-21-23 07:00AM
Jun-13-23 12:40PM
May-24-23 07:00AM
May-09-23 02:00AM
May-04-23 02:00AM
Apr-29-23 01:23AM
Apr-25-23 06:50AM
Apr-17-23 07:05AM
PureTech Health Plc engages in the provision of differentiated medicines for devastating diseases, including inflammatory, fibrotic and immunological conditions, intractable cancers, lymphatic and gastrointestinal diseases and neurological and neuropsychological disorders. It operates through the following segments: Internal, Controlled Founded Entities, Non-Controlled Founded Entities, and Parent Company and Others. The Internal segment focuses on immunological, fibrotic, and lymphatic system mechanisms. The Controlled Founded Entities segment is composed of the group's subsidiaries that are currently consolidated operational subsidiaries that either have or have plans to hire independent management teams and currently have already raised, or are currently in the process of raising, third-party dilutive capital. The Non-Controlled Founded Entities segment includes companies wherein the group no longer holds majority voting control as a shareholder and no longer has the right to elect a majority of the members of the subsidiaries' Board of Directors. The Parent Company and Other segment represents activities that are not directly attributable to the operating segments, such as the activities of the parent, corporate support functions and certain research and development support functions that are not directly attributable to a strategic business segment as well as the elimination of intercompany transactions. The company was founded by Robert S. Langer Jr., Bennett M. Shapiro, and Daphne Zohar on May 8, 2015 and is headquartered in Boston, MA.